![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » PHARMEXA GRANTS PADRE LICENSE TO IMMUNOVACCINE TECHNOLOGIES INC.
PHARMEXA GRANTS PADRE LICENSE TO IMMUNOVACCINE TECHNOLOGIES INC.
August 28, 2006
Pharmexa has entered into a license agreement with ImmunoVaccine Technologies Inc. (IVT) of Halifax, Nova Scotia for the use of PADRE immunostimulatory peptide(s) with IVT's VacciMax vaccines. IVT has a non-exclusive right to use PADRE in combination with up to three different targets for its vaccines. The agreement includes up-front and future payments as well as royalties on sales. Financial details were not disclosed and the agreement will not effect Pharmexa's financial forecasts for 2006. Pipeline Review (http://www.pipelinereview.com/joomla/content/view/6043/118/)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct